Abdominal obesity and the risk of venous thromboembolism among women: A potential role of interleukin-6

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 1, 2013, Pages 29-34

  Matos, Marinez Farana ^a   Lourenço, Dayse Maria ^a   Orikaza, Cristina Mary ^a   Gouveia, Christiane Pereira ^a   Morelli, Vânia Maris ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ABDOMINAL OBESITY; ADULT; AGE; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; VENOUS THROMBOEMBOLISM; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OBESITY, ABDOMINAL; RISK FACTORS; VENOUS THROMBOEMBOLISM; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84872871101     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0077     Document Type: Article

References (41)

1. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: A meta analysis. Circulation 2008;117:93-102.
2. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: Results from the Copenhagen City Heart Study. Circulation 2010;121:1896-1903.
3. Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: Risk factors for venous thromboembolism among middle-aged men: ''The study of men born in 1913.'' Arch Intern Med 1999;159:1886-1890.
4. Severinsen MT, Kristensen SR, Johnsen SP, et al. Anthropometry, body fat, and venous thromboembolism: A Danish follow-up study. Circulation 2009;120:1850-1857.
5. Lutsey PL, Virnig BA, Durham SB, et al. Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study. Am J Public Health 2010;100: 1506-1513.
6. Borch KH, Braekkan SK, Mathiesen EB, et al. Anthropometric measures of obesity and risk of venous thromboembolism: The Tromso study. Arterioscler Thromb Vasc Biol 2010; 30:121-127.
7. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost 2009;35:451-457.
8. Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: A case-control study. J Thromb Haemost 2006;4:1914-1918.
9. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007;92:374-380.
10. Jang MJ, Choi WI, Bang SM, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol 2009;29: 311-315.
11. Di Minno MN, Tufano A, Guida A, et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res 2011;127:193-197.
12. VayaA, Mart?nez-Triguero ML, Espana F, et al. The metabolic syndrome and its individual components: Its association with venous thromboembolism in a mediterranean population. Metab Syndr Relat Disord 2011;9:197-201.
13. Borch KH, Braekkan SK, Mathiesen EB, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: The Tromsø study. J Thromb Haemost 2009;7:739-745.
14. Steffen LM, Cushman M, Peacock JM, et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal investigation of thromboembolism etiology. J Thromb Haemost 2009;7:746-751.
15. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-468.
16. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009;10:554-563.
17. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.
18. Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-137.
19. Folsom AR, Lutsey PL, Astor BC, et al. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009;102: 615-619.
20. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010;95:119-125.
21. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010;30: 1672-1678.
22. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
23. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113:636-642.
24. Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. Microalbuminuria and risk of venous thromboembolism. JAMA 2009;301:1790-1797.
25. Hald EM, Brækkan SK,Mathiesen EB, et al. High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: The Tromso study. Haematologica 2011;96:1189-1194.
26. Matos MF, Lourenco DM, Orikaza CM, et al. The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6-174GC, IL-8-251AT and MCP-1-2518AG in the risk of venous thromboembolism: A case-control study. Thromb Res 2011;128:216-220.
27. van Aken BE, den Heijer M, Bos GM, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000;83:536-539.
28. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: The Leiden Thrombophilia Study. J Thromb Haemost 2004;2:619-622.
29. Poredos P, Jezovnik MK. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels 2011;26:596-602.
30. Vormittag R, Hsieh K, Kaider A, et al. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 2006;95:802-806.
31. Christiansen SC, Naess IA, Cannegieter SC, et al. Inflammatory cytokines as risk factors for a first venous thrombosis: A prospective population-based study. PLoS Med 2006;3:e334.
32. Pena SD, Bastos-Rodrigues L, Pimenta JR, et al. DNA tests probe the genomic ancestry of Brazilians. Braz J Med Biol Res 2009;42:870-876.
33. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
34. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010-1013.
35. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-520.
36. Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997;17: 3399-3405.
37. Lippi G, Favaloro EJ, Montagnana M, et al. C-reactive protein and venous thromboembolism: Causal or casual association? Clin Chem Lab Med 2010;48:1693-1701.
38. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-1861.
39. Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies. Thromb Res 2011;128:422-430.
40. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-1189.
41. Undas A, Celinska-LowenhoffM, Kaczor M, et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004;91:1065-1077.